Ketamine for Older Adults Pilot
This pilot completed single-group study (n=25) assessed safety and feasibility of IV ketamine (0.5 mg/kg infused over 40 minutes) in older adults with treatment-resistant depression, with twice-weekly infusions for 4 weeks and optional weekly continuation for responders.
Details
Single-group interventional pilot in adults ≥65 with treatment-resistant unipolar depression testing IV ketamine 0.5 mg/kg infused over 40 minutes. Acute phase: twice-weekly infusions for 4 weeks; responders/remitters offered weekly continuation infusions for 4 weeks.
Outcomes include feasibility, safety (vitals, adverse events), depressive symptoms (PHQ-9), executive functioning, and daily mobile health symptom surveys to evaluate precision-medicine approaches.
Assessments at baseline, end of acute phase, and end of continuation phase; study developed methods for mobile health and precision approaches in late-life depression.